Sugi Predict

Sugi Predict / Compounds / SCHEMBL3095604

SCHEMBL3095604

SCHEMBL3095604

Cc1oc(-c2ccccc2)cc1C(Nc1ccc(C(=O)NCCC(=O)O)cc1)C1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCG P01275 10/20 0.46
▸ GCGR P47871 5/20 0.40
▸ ADCY6 O43306 3/20 0.40
▸ ADCY3 O60266 3/20 0.40
▸ ADCY9 O60503 3/20 0.40
▸ ADCY5 O95622 3/20 0.40
▸ ADCY8 P40145 3/20 0.40
▸ ADCY7 P51828 3/20 0.40
▸ ADCY2 Q08462 3/20 0.40
▸ ADCY1 Q08828 3/20 0.40
▸ ADCY4 Q8NFM4 3/20 0.40
▸ ALDH1A1 P00352 4/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ HPGD P15428 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094745 0.93 GCG (0.45) GCGGCGRADCY6ADCY3ADCY9
SCHEMBL3106711 0.93 GCG (0.46) GCGGCGRADCY6ADCY3ADCY9
SCHEMBL3102193 0.92 GCG (0.46) GCGGCGRADCY6ADCY3ADCY9
SCHEMBL3102044 0.91 GCG (0.41) GCGGCGRADCY6ADCY3ADCY9
SCHEMBL3109979 0.91 GCG (0.43) GCGGCGRADCY6ADCY3ADCY9
SCHEMBL3102375 0.89 GCGR (0.42) GCGGCGRADCY6ADCY3ADCY9
SCHEMBL3102051 0.86 ALDH1A1 (0.46) ALDH1A1MEN1KMT2AHPGDCYP1A2
SCHEMBL3101489 0.85 ALDH1A1 (0.40) GCGALDH1A1MEN1KMT2AHPGD
SCHEMBL3102129 0.85 GCG (0.46) GCGGCGR
SCHEMBL3107662 0.85 GCG (0.52) GCGGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 — — EP disclosed
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 — — EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 — — US disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 — — US disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 — — US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 — — US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 — — US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 — — US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 — — EP disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR GCG 11/4885GCGR 3/4885ADCY6 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.